Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... azacitidine . METHODS: A phase 2 randomized, placebo -controlled clinical trial of azacitidine and pracinostat ... there were 51 in the pracinostat group and 51 in the placebo group. The median age was 69 years. The CR rate by cycle 6 of therapy ...

    Research Article last updated 02/03/2017 - 11:12am.

  2. Advances in antiviral drug cuts infection post SCT

    ... research centers in 20 countries, compared letermovir to placebo in preventing an active CMV infection following transplant with ... weeks of treatment, 61 percent of the patients receiving a placebo had developed a CMV infection serious enough to require treatment or ...

    Article last updated 02/23/2017 - 7:26am.

  3. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... Based on the results of this study, the randomized, placebo -controlled phase 3 QUAZAR Lower-Risk MDS trial (AZA-MDS-003) was ... design and rationale for this trial comparing CC-486 with placebo for the treatment of patients with IPSS lower-risk MDS with poor ...

    Research Article last updated 06/23/2016 - 10:17am.

  4. Taming the nausea, vomiting caused by chemo

    ... to treat nausea/vomiting than patients who received a placebo plus the three antiemetic drugs. The investigators believe the ... were randomly assigned to receive olanzapine or a placebo, in combination with the other three drugs, immediately before and for ...

    Article last updated 08/11/2016 - 3:27pm.

  5. Self-injected PNH therapy on the horizon

    ... most people miss" in the disease is that "there is no placebo response. It doesn't happen" in phase III trials. "We actually have ...

    Article last updated 07/07/2016 - 9:40am.

  6. MEDALIST Trial

    ... This is a Phase 3, double-blind, randomized, placebo -controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to International Prognostic ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  7. A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients

    ... This multi center randomized (1:1), double blind, placebo controlled Phase 1b/2 study is designed to compare the safety, ... (PK), and pharmacodynamics (PD) of PF 04449913 or placebo when combined with azacitidine in patients with previously ...

    Clinical Trial last updated 04/27/2016 - 1:20pm.

  8. Clinical Trials: What Are Phases, and What Happens in Each One?

    ... everyone in the trial gets the drug. There is often no placebo arm of this trial. This is called a ‘single arm’ study. However ... newer Phase 2 designs do have a control arm, whether it is a placebo or another therapy – and this is known as a two-arm study. By ...

    Interview last updated 11/16/2015 - 8:32am.

  9. A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

    ... THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW, OR ... Drug: Luspatercept Other Name: ACE-536 Other: Placebo ...

    Clinical Trial last updated 04/21/2016 - 1:16pm.

  10. Interviews with the Experts: Side Effects of PNH Treatment

    ... receiving eculizumab and 9 (21%) patients receiving placebo (inactive ingredient). Among 193 patients with PNH treated with ...

    Interview last updated 08/31/2016 - 8:37am.